About GeneDx
GeneDx is a company based in Stamford (United States) founded in 2017. It operates as a HealthTech and Professional Services. GeneDx has raised $241 million across 3 funding rounds from investors including Pfizer, Blackstone and BlackRock. GeneDx has completed 2 acquisitions, including GeneDx and LifeMap Solutions. GeneDx offers products and services including ExomeDx, GenomeDx, and GenomeDx Rapid. GeneDx operates in a competitive market with competitors including ArcherDX, Natera, Variantyx, ImaginAb and RareCyte, among others.
- Headquarter Stamford, United States
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Genedx, Llc
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of GeneDx
GeneDx offers a comprehensive portfolio of products and services, including ExomeDx, GenomeDx, and GenomeDx Rapid.
Exome sequencing is provided for higher diagnostic yield.
Comprehensive genome sequencing includes mitochondrial genome analysis.
Rapid genome sequencing aids infants in intensive care.
People of GeneDx
Unlock access to complete
Unlock access to complete
Leadership Team
20 people
Software Development Team
8 people
Finance and Accounting
7 people
Sales and Marketing
6 people
Operations Team
5 people
Board Team
5 people
Human Resources and Administration
4 people
Data Analysis and Operations Team
4 people
Unlock access to complete
Funding Insights of GeneDx
GeneDx has successfully raised a total of $241M across 3 strategic funding rounds. The most recent funding activity was a Post-IPO round of $200 million completed in May 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in GeneDx
GeneDx has secured backing from 8 investors, including institutional and venture fund investors. Prominent investors backing the company include Pfizer, Blackstone and BlackRock.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Healthcare ecosystem is supported through investment and innovation by Deerfield.
|
Locked | Locked | Locked | |
|
Diversified investment management is provided across multiple asset classes.
|
Locked | Locked | Locked | |
|
Venture capital investments are made in innovative technology startups.
|
Locked | Locked | Locked |
Investor details for GeneDx
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by GeneDx
GeneDx has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include GeneDx and LifeMap Solutions.
Investment portfolio details for GeneDx
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Mobile apps for asthma management
|
Locked | Locked | 2014 | Locked | |
|
Genetic testing for inherited disorders is provided by the company.
|
Locked | Locked | 2000 | Locked |
Complete acquisition details for GeneDx
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - GeneDx
Detailed financials for GeneDx
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Genedx Comparisons
Peer comparison for GeneDx
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of GeneDx
GeneDx operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as ArcherDX, Natera, Variantyx, ImaginAb and RareCyte, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Molecular cancer diagnostic products are developed using patented AMP technology.
|
|
| Locked | Locked | Locked |
Developer of cell-free DNA testing for oncology, women’s health, and organ health
|
|
| Locked | Locked | Locked |
Genomics data analysis platform for healthcare diagnostics is offered.
|
|
| Locked | Locked | Locked |
ImaginAb is focused on developing advanced immuno-oncology imaging technologies.
|
|
| Locked | Locked | Locked |
Developer of technologies for the analysis of rare and single cells in the blood
|
|
| Locked | Locked | Locked |
Genetic sequencing is provided for late-stage cancer patients.
|
Detailed competitors of GeneDx
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Genedx
Complete news archive for GeneDx
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about GeneDx
GeneDx was founded in 2017 and raised its 1st funding round 2 years after it was founded.
GeneDx is headquartered in Stamford, United States. It is registered at Stamford, Connecticut, United States.
GeneDx is a funded company, having raised a total of $241M across 3 funding rounds to date.
GeneDx is involved in providing advanced genomic and exome testing services to healthcare providers and patients. The company focuses on diagnosing genetic disorders through comprehensive tests like ExomeDx and GenomeDx, targeting conditions such as developmental disorders, epilepsy, autism, and cerebral palsy. Operating in the healthcare and biotechnology sector, GeneDx supports rapid diagnosis for critically ill infants and offers actionable results with clinical expertise. Their solutions are recommended as first-line tests by medical guidelines, aiming to prevent disease progression and improve patient outcomes.
GeneDx's top competitors include Natera, ImaginAb and Lantern Pharma.
GeneDx offers ExomeDx, GenomeDx, and GenomeDx Rapid.
GeneDx has made 2 acquisitions, including GeneDx, and LifeMap Solutions.
GeneDx has 8 investors. Key investors include Pfizer, Blackstone, BlackRock, Deerfield, and S32.